Curantil N25, 25 mg 120 pcs

Curantil – angioprotective, antiaggregative, immunomodulatory.

Competitively inhibits adenosine deaminase, promoting the accumulation of adenosine, involved in the regulation of coronary blood flow, as well as platelet aggregation and adhesion ability. It blocks phosphodiesterase and increases the content of cAMP in cells. As a pyrimidine derivative, Curantil is an interferon inducer and has a modulatory effect on the functional activity of the interferon system; increases nonspecific antiviral resistance to viral infections.

Pharmacodynamics

Lower resistance of the coronary arteries at the level of small branches and arterioles, increases the number of collaterals and collateral blood flow; Increases adenosine concentration and ATP synthesis in the myocardium, improves myocardial contractility, decreases PPS, lowers BP, inhibits platelet aggregation (improves microcirculation, prevents arterial thrombosis), normalizes venous outflow; Lowers resistance of cerebral vessels, corrects placental blood flow; at risk of preeclampsia prevents dystrophic changes in the placenta, eliminates hypoxia of fetal tissues, promotes the accumulation of glycogen in them; has a modulating effect on the functional activity of the interferon system, increases nonspecific antiviral resistance to viral infections.

Pharmacokinetics

It is rapidly absorbed from the stomach (most of it) and small intestine (a small amount). Almost completely bound to plasma proteins. Cmax is within 1 h after ingestion. It accumulates primarily in the heart and erythrocytes.

Metabolized by the liver by binding to glucuronic acid, excreted in the bile as monoglucuronide. For tablets T1/2 is 10 h ± 2.2 h.

Indications

– Treatment and prevention of impaired cerebral circulation,

– dyscirculatory encephalopathy,

– prevention of arterial and venous thrombosis and its complications,

–

– as a complex therapy for any disorders of microcirculation,

– as an interferon inducer and immunomodulator for prevention and treatment of flu, SARS.

Active ingredient

Composition

Active ingredients:

dipyridamole 25 mg.

Associates:

corn starch – 67.75 mg,

lactose monohydrate – 28.5 mg,

gelatin – 2.5 mg,

sodium carboxymethyl starch (type A) – 3.75 mg,

colloidal anhydrous silica – 1.25 mg,

magnesium stearate – 1.25 mg.

Composition of the film coating: Hypromellose – 0.9 mg, talc – 0.4 mg, macrogol 6000 – 1.2 mg, titanium dioxide (E171) – 0.1 mg, quinoline yellow dye (E104) – 0.008 mg, simethicone emulsion – 0.002 mg.

How to take, the dosage

The dose of the drug is chosen depending on the severity of the disease and the individual response of the patient.

In case of CHD, it is recommended to take 75 mg 3 times a day. If necessary, the daily dose can be increased under medical supervision.

For the prevention and treatment of cerebral circulatory disorders, as well as for prophylaxis, 75 mg 3-6 times a day is prescribed. The maximum daily dose is 450 mg.

To reduce platelet aggregation, Courantil is prescribed in a dose of 75-225 mg/day in several doses. In severe cases, the dose may be increased to 600 mg/day.

For prevention of flu and acute respiratory viral infections, especially during epidemics, Courantil N25 and Courantil 25 are prescribed in 50 mg (2 tablets or 2 pills)/day in 1 dose. The drug is taken once a week for 4-5 weeks.

In prophylaxis of recurrent ARVI in patients who have often had respiratory viral infections Courantil N25 and Courantil 25 are prescribed in dose 100 mg/day (2 tablets or 2 tablets/drags 2 times/day with 2 hours interval between doses). The drug is taken once a week for 8-10 weeks.

The tablets should be taken on an empty stomach, without breaking or biting, with a small amount of liquid. The duration of the course of treatment is determined by the doctor.

Interaction

Concomitant use of Curantil with anticoagulants or acetylsalicylic acid increases the antithrombotic effect of the latter and therefore the risk of hemorrhagic complications.

In concomitant use Curantil increases the effect of antihypertensive drugs.

When used concomitantly, Curantil may impair the anticholinergic effects of cholinesterase inhibitors.

When used concomitantly, xanthine derivatives weaken the vasodilatory effects of Curantil.

Special Instructions

The vasodilator effect of Curantil may decrease if tea or coffee (containing xanthine derivatives) is taken at the same time.

Pediatric use

Curantil is not recommended for children under 12 years of age due to lack of sufficient clinical experience with its use.

Influence on ability to drive vehicles and other mechanisms requiring increased concentration

Caution should be exercised when driving motor vehicles and operating machinery because the ability to concentrate and quick psychomotor reactions may be impaired as a result of a drop in blood pressure while taking Curantil.

Contraindications

– Hypersensitivity,

– acute myocardial infarction,

– unstable angina pectoris,

– stenotic atherosclerosis of the coronary arteries,

– decompensated heart failure,

– subaortic stenosis,

– hypotension and hypertension (severe forms),

– collapse,

– arrhythmia,

– gastric and duodenal ulcer (acute),

/p>

– hepatic and/or renal insufficiency,

– hemorrhagic diathesis,

– under 12 years of age.

Side effects

Cardiovascular system disorders: palpitations, tachycardia (especially with concomitant use of other vasodilators), bradycardia, facial flushes, facial hyperemia, coronary embolism syndrome (when using the drug in a dose greater than 225 mg/day), BP decrease.

The digestive system: nausea, vomiting, diarrhea, epigastric pain. Usually these side effects disappear with longer use of the drug.

With the clotting system: thrombocytopenia, changes in the functional properties of platelets, bleeding; in single cases – increased bleeding during or after surgery.

CNS side: dizziness, head noise, headache.

Allergic reactions: skin rash, urticaria.

Others:weakness, feeling of stuffy ear, arthritis, myalgia, rhinitis.

When the drug is used in therapeutic doses, the side effects are usually mild and transient.

Overdose

Symptoms: decreased BP, angina pectoris, tachycardia, hot flashes, weakness and dizziness.

Treatment: induced vomiting, gastric lavage, administration of activated charcoal. The vasoconstrictor effect of the drug may be stopped by slow (50-100 mg/min) IV administration of aminophylline. If symptoms of angina persist, administration of nitroglycerin sublingually.

Pregnancy use

The drug may be used in pregnancy when indicated.

The use of the drug during lactation is possible only if the expected benefits of treatment exceed the possible risks.

Similarities